IL295120A - alpha-hydroxylated fatty-acid metabolites, their medical uses and their use as biomarkers - Google Patents

alpha-hydroxylated fatty-acid metabolites, their medical uses and their use as biomarkers

Info

Publication number
IL295120A
IL295120A IL295120A IL29512022A IL295120A IL 295120 A IL295120 A IL 295120A IL 295120 A IL295120 A IL 295120A IL 29512022 A IL29512022 A IL 29512022A IL 295120 A IL295120 A IL 295120A
Authority
IL
Israel
Prior art keywords
riu0003
compound
khu0003
formula
wkhu0003
Prior art date
Application number
IL295120A
Other languages
English (en)
Hebrew (he)
Inventor
Ruiz Pablo Vicente Escrib?
Canalejo Manuel Torres
Xaubet Xavier Busquets
CA?ELLAS Victoria LLAD?
GARC?A Paula FERN?NDEZ
CASTILLO Catalina Ana ROSSELL?
Barrios Sebasti? Parets
Gobel Roberto Beteta
Urrego Emilce Cano
Gonz?Lez Laura Arbona
Lorca Raquel Rodr?Guez
BAUZ? Juan CABOT
PIZ? Marc MILLARES
Original Assignee
Univ Illes Balears
Ruiz Pablo Vicente Escrib?
Canalejo Manuel Torres
Xaubet Xavier Busquets
CA?ELLAS Victoria LLAD?
GARC?A Paula FERN?NDEZ
CASTILLO Catalina Ana ROSSELL?
Barrios Sebasti? Parets
Gobel Roberto Beteta
Urrego Emilce Cano
Gonz?Lez Laura Arbona
Lorca Raquel Rodr?Guez
BAUZ? Juan CABOT
PIZ? Marc MILLARES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES202030070A external-priority patent/ES2846824B2/es
Priority claimed from ES202031155A external-priority patent/ES2911474B2/es
Application filed by Univ Illes Balears, Ruiz Pablo Vicente Escrib?, Canalejo Manuel Torres, Xaubet Xavier Busquets, CA?ELLAS Victoria LLAD?, GARC?A Paula FERN?NDEZ, CASTILLO Catalina Ana ROSSELL?, Barrios Sebasti? Parets, Gobel Roberto Beteta, Urrego Emilce Cano, Gonz?Lez Laura Arbona, Lorca Raquel Rodr?Guez, BAUZ? Juan CABOT, PIZ? Marc MILLARES filed Critical Univ Illes Balears
Publication of IL295120A publication Critical patent/IL295120A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL295120A 2020-01-29 2021-01-28 alpha-hydroxylated fatty-acid metabolites, their medical uses and their use as biomarkers IL295120A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES202030070A ES2846824B2 (es) 2020-01-29 2020-01-29 Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
EP20382145 2020-02-28
ES202031155A ES2911474B2 (es) 2020-11-17 2020-11-17 Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
PCT/ES2021/070068 WO2021152201A2 (es) 2020-01-29 2021-01-28 Metabolitos de ácidos grasos alfa-hidroxilados, usos médicos de los mismos y uso como biomarcadores

Publications (1)

Publication Number Publication Date
IL295120A true IL295120A (en) 2022-09-01

Family

ID=77078835

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295120A IL295120A (en) 2020-01-29 2021-01-28 alpha-hydroxylated fatty-acid metabolites, their medical uses and their use as biomarkers

Country Status (12)

Country Link
US (1) US20230097753A1 (enExample)
EP (1) EP4098649A4 (enExample)
JP (1) JP7736313B2 (enExample)
KR (1) KR20220132552A (enExample)
CN (1) CN115052852A (enExample)
AU (2) AU2021212330A1 (enExample)
BR (1) BR112022015172A2 (enExample)
CA (2) CA3233141A1 (enExample)
CL (1) CL2022001985A1 (enExample)
IL (1) IL295120A (enExample)
MX (1) MX2022009035A (enExample)
WO (1) WO2021152201A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
ES2982396A1 (es) * 2023-03-14 2024-10-15 Veritas Therapeutics S L 2-hidroxi-octadecen-9-cis-oato para uso en el tratamiento de patologias oncologicas y del dolor neuropatico

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195296B (de) * 1958-06-28 1965-06-24 Dr Gernot Grimmer Verfahren zur Herstellung von entzuendungs- und oedemhemmenden Salzen der cis-9-Pentadecensaeure und der cis-9-Heptadecensaeure
DE1147221B (de) * 1958-06-28 1963-04-18 Dr Rer Nat Gernot Grimmer Verfahren zur Herstellung von entzuendungs- und oedemhemmenden Salzen der Pentadecen- und Heptadecensaeuren
GB1156465A (en) * 1967-02-16 1969-06-25 Unilever Ltd Prostaglandins
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB9926833D0 (en) * 1999-11-15 2000-01-12 Univ Sunderland Compositions
DE102007055344A1 (de) * 2007-11-19 2009-05-20 K. D. Pharma Bexbach Gmbh Neue Verwendung von Omega-3-Fettsäure(n)
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
KR20120065276A (ko) * 2009-05-29 2012-06-20 뉴 챕터, 인코포레이티드. 지질 조성을 조정하기 위한 조성물 및 방법
CN102276444B (zh) * 2011-05-04 2013-10-09 厦门大学 脂肪酸类化合物及其制备方法与应用
ES2401629B1 (es) 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
WO2014113584A1 (en) * 2013-01-16 2014-07-24 Rhode Island Hospital Compositions and methods for the prevention and treatment of osteolysis and osteoporosis
US20150173410A1 (en) * 2013-12-19 2015-06-25 Change Cola, Inc. Beverage comprising omega fatty acid
JP2016222590A (ja) * 2015-05-29 2016-12-28 国立大学法人東京海洋大学 脂肪酸の同位体標識化合物の製造方法およびその方法により得られた脂肪酸の同位体標識化合物、ならびに診断薬
WO2019241728A1 (en) * 2018-06-15 2019-12-19 Youhealth Biotech, Limited Composition and methods for modulation of elovl2

Also Published As

Publication number Publication date
AU2023248158B2 (en) 2025-11-27
AU2021212330A1 (en) 2022-09-22
EP4098649A4 (en) 2024-04-17
BR112022015172A2 (pt) 2022-10-11
AU2023248158A1 (en) 2023-11-02
CL2022001985A1 (es) 2023-02-03
WO2021152201A2 (es) 2021-08-05
CN115052852A (zh) 2022-09-13
WO2021152201A3 (es) 2021-09-23
MX2022009035A (es) 2022-08-11
JP7736313B2 (ja) 2025-09-09
KR20220132552A (ko) 2022-09-30
US20230097753A1 (en) 2023-03-30
CA3166307C (en) 2024-05-21
CA3233141A1 (en) 2021-08-05
CA3166307A1 (en) 2021-08-05
EP4098649A2 (en) 2022-12-07
JP2023518640A (ja) 2023-05-08

Similar Documents

Publication Publication Date Title
EP4122920A1 (en) Lipid compound as well as lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing same
JP6766126B2 (ja) グリコサミノグリカン誘導体及びその製造方法
EP2751081B1 (en) Polymorphic form of pitavastatin calcium
US10953037B2 (en) Chondroitin sulfate derivative and agent for treating bladder diseases
TNSN08348A1 (en) Antibiotic compositions of modified release and process of production thereof
ZA200504940B (en) Amino acid derived prodrugs of propofol, compositions and uses thereof
EP4234482A2 (en) Copper nanoclusters, composition comprising the same, and treatment of neurodegenerative diseases
HUP1000120A2 (en) Stabilized pharmaceutical composition containing gaba analog and hydrogenated disaccharide and/or polyol
EP2436364B1 (de) Lackzusammensetzung umfassend ein Monomer mit einem polyalicyclischen Strukturelement
EP2530068A1 (en) New strontium salts, synthesis and use thereof in the treatment of osteoporosis
Skrtic et al. Dental composites: Bioactive polymeric amorphous calcium phosphate-based
EP4039279A1 (en) Transmucosal delivery system for medicinal active ingredient to submucosa of bladder
HK40039515A (en) Chondroitin sulfate derivative and agent for treating bladder diseases
US20190151264A1 (en) Methods for treatment of prader-willi syndrome
US20140348931A1 (en) Sustained-release topiramate formulations
JP2024540425A (ja) 薬物コンジュゲートならびにその調製方法および使用方法
KR20240071344A (ko) Lipid Nanoparticle에 담지된 신규 화합물, 이의 제조방법 및 이를 포함하는 항생제 조성물
EP4230624A1 (en) Quinazoline-2,4-diamine derivative and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient
EP1532975A1 (de) Verfahren zur Herstellung von freifliessenden, pulverförmigen Atorvastatin-Adsorbaten
JP2026509295A (ja) 非オピオイド薬物のためのナノ粒子製剤
JP2025514198A (ja) 二重機能免疫調節化合物、製剤、及びその使用
Skrtic et al. Bioactive ACP-based polymeric biocomposites
HK40038937B (en) Conjugates of stanozolol and hyaluronic acid
CN110585213A (zh) 遮光剂及其组合物
Bandini et al. Trattamento della iperfosforemia del paziente uremico: I nuovi chelanti